Nandrolone laurateCAS# 26490-31-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 26490-31-3 | SDF | Download SDF |
PubChem ID | 94371 | Appearance | Powder |
Formula | C30H48O3 | M.Wt | 456.7 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] dodecanoate | ||
SMILES | CCCCCCCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C | ||
Standard InChIKey | OXXNTXVXBWLYQE-PVHICTMWSA-N | ||
Standard InChI | InChI=1S/C30H48O3/c1-3-4-5-6-7-8-9-10-11-12-29(32)33-28-18-17-27-26-15-13-22-21-23(31)14-16-24(22)25(26)19-20-30(27,28)2/h21,24-28H,3-20H2,1-2H3/t24-,25+,26+,27-,28-,30-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Nandrolone laurate Dilution Calculator
Nandrolone laurate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1896 mL | 10.9481 mL | 21.8962 mL | 43.7924 mL | 54.7405 mL |
5 mM | 0.4379 mL | 2.1896 mL | 4.3792 mL | 8.7585 mL | 10.9481 mL |
10 mM | 0.219 mL | 1.0948 mL | 2.1896 mL | 4.3792 mL | 5.4741 mL |
50 mM | 0.0438 mL | 0.219 mL | 0.4379 mL | 0.8758 mL | 1.0948 mL |
100 mM | 0.0219 mL | 0.1095 mL | 0.219 mL | 0.4379 mL | 0.5474 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Clovanediol diacetate
Catalog No.:BCN5144
CAS No.:2649-68-5
- Clovanediol
Catalog No.:BCN5143
CAS No.:2649-64-1
- Cyclo(D-Phe-L-Pro)
Catalog No.:BCN4011
CAS No.:26488-24-4
- 6-Deoxyisojacareubin
Catalog No.:BCN7723
CAS No.:26486-92-0
- Catharanthine Tartrate
Catalog No.:BCN2462
CAS No.:2648-21-5
- Humulone
Catalog No.:BCN2682
CAS No.:26472-41-3
- 26-Deoxyactein
Catalog No.:BCN8076
CAS No.:264624-38-6
- MRS 1754
Catalog No.:BCC7473
CAS No.:264622-58-4
- MRS 1706
Catalog No.:BCC7120
CAS No.:264622-53-9
- SSR 146977 hydrochloride
Catalog No.:BCC7635
CAS No.:264618-38-4
- PR-619
Catalog No.:BCC3627
CAS No.:2645-32-1
- Bz-Arg-OEt.HCl
Catalog No.:BCC2686
CAS No.:2645-08-1
- Z-Gln-OH
Catalog No.:BCC2783
CAS No.:2650-64-8
- Methyleugenolglycol
Catalog No.:BCN6562
CAS No.:26509-45-5
- N-[Bis(methylthio)methylene]- p-toluenesulfonamide
Catalog No.:BCC9069
CAS No.:2651-15-2
- Taiwanhomoflavone A
Catalog No.:BCN6853
CAS No.:265120-00-1
- Fosaprepitant dimeglumine salt
Catalog No.:BCC4954
CAS No.:265121-04-8
- GW 7647
Catalog No.:BCC7150
CAS No.:265129-71-3
- Ryuvidine
Catalog No.:BCC7432
CAS No.:265312-55-8
- (-)-Hinokinin
Catalog No.:BCN3227
CAS No.:26543-89-5
- Apiin
Catalog No.:BCN2311
CAS No.:26544-34-3
- 8-Phenyloctanoic acid
Catalog No.:BCC8790
CAS No.:26547-51-3
- 2,3-Dihydroxy-12-oleanen-28-oic acid
Catalog No.:BCN5145
CAS No.:26563-68-8
- 3-Hydroxycatalponol
Catalog No.:BCN5146
CAS No.:265644-24-4
Monitoring the endogenous steroid profile disruption in urine and blood upon nandrolone administration: An efficient and innovative strategy to screen for nandrolone abuse in entire male horses.[Pubmed:23949888]
Drug Test Anal. 2014 Apr;6(4):376-88.
Nandrolone (17beta-hydroxy-4-estren-3-one) is amongst the most misused endogenous steroid hormones in entire male horses. The detection of such a substance is challenging with regard to its endogenous presence. The current international threshold level for nandrolone misuse is based on the urinary concentration ratio of 5alpha-estrane-3beta,17alpha-diol (EAD) to 5(10)-estrene-3beta,17alpha-diol (EED). This ratio, however, can be influenced by a number of factors due to existing intra- and inter-variability standing, respectively, for the variation occurring in endogenous steroids concentration levels in a single subject and the variation in those same concentration levels observed between different subjects. Targeting an efficient detection of nandrolone misuse in entire male horses, an analytical strategy was set up in order to profile a group of endogenous steroids in nandrolone-treated and non-treated equines. Experiment plasma and urine samples were steadily collected over more than three months from a stallion administered with Nandrolone laurate (1 mg/kg). Control plasma and urine samples were collected monthly from seven non-treated stallions over a one-year period. A large panel of steroids of interest (n = 23) were extracted from equine urine and plasma samples using a C18 cartridge. Following a methanolysis step, liquid-liquid and solid-phase extractions purifications were performed before derivatization and analysis on gas chromatography-tandem mass spectrometry (GC-MS/MS) for quantification. Statistical processing of the collected data permitted to establish statistical models capable of discriminating control samples from those collected during the three months following administration. Furthermore, these statistical models succeeded in predicting the compliance status of additional samples collected from racing horses.
Ultra high performance liquid chromatography/tandem mass spectrometry based identification of steroid esters in serum and plasma: an efficient strategy to detect natural steroids abuse in breeding and racing animals.[Pubmed:23484650]
J Chromatogr A. 2013 Apr 5;1284:126-40.
During last decades, the use of natural steroids in racing and food producing animals for doping purposes has been flourishing. The endogenous or exogenous origin of these naturally occurring steroids has since remained a challenge for the different anti-doping laboratories. The administration of these substances to animals is usually made through an intra-muscular pathway with the steroid under its ester form for a higher bioavailability and a longer lasting effect. Detecting these steroid esters would provide an unequivocal proof of an exogenous administration of the considered naturally occurring steroids. A quick analytical method able to detect at trace level (below 50 pg/mL) a large panel of more than 20 steroid esters in serum and plasma potentially used for doping purposes in bovine and equine has been developed. Following a pre-treatment step, the sample is submitted to a solid phase extraction (SPE) before analysis with UPLC-MS/MS. The analytical method's efficiency has been probed through three different in vivo experiments involving testosterone propionate intra-muscular administration to three heifers, 17-estradiol benzoate intra-muscular administration to a bull and a heifer and Nandrolone laurate intra-muscular administration to a stallion. The results enabled detecting the injected testosterone propionate and 17-estradiol benzoate 2 and 17 days, respectively, post-administration in bovine and Nandrolone laurate up to 14 days post-administration in equine. The corresponding elimination profiles in bovine serum and equine plasma have been established. The first bovine experiment exhibited a maximal testosterone propionate concentration of 400 pg/mL in one of the three heifer serum within 5h post-administration. The second bovine experiment reported a maximal 17-estradiol benzoate concentration of 480 pg/mL in the same matrix recorded 9 days after its administration. The last equine experiment resulted in a maximal Nandrolone laurate concentration of 440 pg/mL in horse plasma 24h after administration.
Double-blind, placebo-controlled study of the efficacy of nandrolone laurate in the treatment of dobermanns with subclinical hepatitis.[Pubmed:16155239]
Vet Rec. 2005 Sep 10;157(11):313.
Twenty-one three-year-old dobermanns with subclinical hepatitis were treated with Nandrolone laurate or a placebo in a double-blind trial. The dogs were scored clinically before and after four months of treatment and they were evaluated by clinical biochemistry and liver biopsies. After the treatment no significant differences were observed between the two groups in any of the clinical biochemistry values; eight of the 21 dogs had no histological evidence of hepatitis and five other dogs had improved, but there was no significant difference between the responses of the two groups.
Proposed mechanisms for the anabolic steroid-induced increase in myocardial susceptibility to ischaemia/reperfusion injury.[Pubmed:15778771]
Cardiovasc J S Afr. 2005 Jan-Feb;16(1):21-8.
UNLABELLED: Androgenic anabolic steroids (AAS) are often used by athletes to enhance athletic performance but are strongly associated with detrimental cardiovascular effects including sudden cardiac death. HYPOTHESIS: AAS use increases myocardial susceptibility to ischaemia/reperfusion injury. METHODS: Rats were trained (swimming) with or without intramuscular injection of Nandrolone laurate (0.375 mg/kg). Untrained rats with or without nandrolone served as controls. Hearts were mounted on the Langendorff perfusion apparatus and mechanical function was measured before and after 20-min normothermic global ischaemia. Myocardial tissue samples were collected for determination of tissue cyclic nucleotide and TNFalpha concentrations. RESULTS: Anabolic steroids decreased the rate pressure product (RPP) of the exercise-trained rat heart [34 582 +/- 1 778 mmHg/min vs 28 868 +/- 2 446 mmHg/min for exercise-trained steroid-treated hearts (p < 0.05)]. Reperfusion RPP was lower in both the sedentary, and the exercise-trained, steroid-treated hearts than in their concurrent vehicle-treated controls (18 276 +/- 2 026 mmHg/min vs 12 018 +/- 1 725 mmHg/min for sedentary steroid-treated hearts and, 21 892 +/- 2 912 mmHg vs 12 838 +/- 1 536 mmHg/min for exercise-trained steroid-treated hearts). Myocardial TNFalpha [267.75 +/- 44.25 pg/g vs 190.00 +/- 15.75 pg/g (p < 0.05)] and cAMP concentrations [406.04 +/- 18.41 pmol/g vs 235.6 +/- 43.26 pmol/g (p < 0.05)] were elevated in the steroid-treated hearts when compared with their untreated counterparts. CONCLUSIONS: Supraphysiological doses of anabolic steroids, whether taken during exercise training or under sedentary conditions increase myocardial susceptibility to ischaemia/reperfusion injury in our model. This increased susceptibility may be related to steroid-induced increases in the pre-ischaemic myocardial cAMP concentrations and/or increases in both pre-ischaemic and reperfusion TNFalpha concentrations.
Effects of nandrolone treatment on recovery in horses after strenuous physical exercise.[Pubmed:11554492]
J Vet Med A Physiol Pathol Clin Med. 2001 Aug;48(6):343-52.
To test the effect of nandrolone on their recovery, six adult half-bred riding horses performed a competition exercise test (CET) and a standardized exercise test (SET) on consecutive days before and after a 2-week treatment with the anabolic steroid Nandrolone laurate. Blood samples were collected during and between these tests for the determination of red cell volume and concentrations of blood lactate, plasma glucose, non-esterified fatty acids, glycerol, triglycrides, erythropoietin, cortisol, insulin, and glucagon. Muscle biopsy specimens were taken immediately after the CET and before the SET for analysis of glycogen content, citrate synthase, and 3-hydroxyacyl CoA dehvdrogenase activity. Nandrolone administration increased the rate of muscle glycogen repletion after exercise, an increase that may be explained by increased glucose output by the liver, higher plasma insulin concentration, and increased insulin-independent glucose transport, but not by better availability of lipid fuels during recovery.